Fertility Assessment and Diagnosis

Fertility assessment begins with a clear understanding of the terminology that clinicians use to describe reproductive function, pathology, and diagnostic procedures. Mastery of these key terms enables health‑care professionals to communicate precisely, interpret test results accurately, and develop appropriate management plans for individuals or couples seeking assistance with conception or navigating menopause‑related changes. The following exposition outlines the most frequently encountered vocabulary, organized by anatomical focus, hormonal markers, laboratory investigations, imaging techniques, and common clinical syndromes. Each entry includes a definition, practical application, illustrative example, and discussion of potential challenges that may arise in clinical practice.

Anovulation – The absence of ovulation during a menstrual cycle. Women who experience anovulation typically present with irregular or absent periods and may have underlying endocrine disorders such as polycystic ovary syndrome (PCOS) or hyperprolactinemia. In practice, a clinician confirms anovulation by tracking basal body temperature, measuring mid‑cycle luteinizing hormone (LH) surge, or assessing serum progesterone in the luteal phase. A common challenge is differentiating true anovulation from luteal‑phase defects, which requires multiple cycle assessments.

Ovulation – The release of a mature oocyte from the dominant follicle, usually occurring around day 14 of a 28‑day cycle. Ovulation is a cornerstone event for natural conception and is the target of many fertility‑enhancing interventions. For example, timed intercourse or intrauterine insemination (IUI) is scheduled based on the predicted ovulation window, often identified through ovulation predictor kits that detect the LH surge.

Luteal phase – The post‑ovulatory segment of the menstrual cycle, lasting approximately 14 days, during which the corpus luteum secretes progesterone to prepare the endometrium for implantation. Inadequate luteal‑phase progesterone can lead to early pregnancy loss. Clinicians may prescribe luteal‑phase support (e.G., Vaginal progesterone) in assisted reproductive technology (ART) cycles to mitigate this risk.

Follicular phase – The interval from the first day of menstruation to the onset of ovulation. During this phase, follicle‑stimulating hormone (FSH) stimulates the growth of ovarian follicles. Monitoring follicular development via transvaginal ultrasound is essential in controlled ovarian stimulation (COS) protocols to avoid hyperstimulation and to time oocyte retrieval.

Ovarian reserve – The quantity and quality of a woman’s remaining oocytes. It is assessed using biomarkers such as anti‑Müllerian hormone (AMH) and antral follicle count (AFC). A diminished ovarian reserve (DOR) suggests reduced fertility potential and may influence the choice of treatment, prompting earlier use of donor oocytes or modified stimulation protocols. Interpretation can be challenging because AMH levels naturally decline with age, and inter‑assay variability may affect clinical decision‑making.

Anti‑Müllerian hormone – A glycoprotein secreted by granulosa cells of pre‑antral and small antral follicles. AMH is considered the most reliable single marker of ovarian reserve because it remains relatively stable throughout the menstrual cycle. In practice, an AMH level below 1.0 Ng/mL in a woman under 35 often signals DOR, whereas levels above 3.0 Ng/mL may indicate a high follicular response risk. Limitations include assay differences and the influence of hormonal contraceptives on measured values.

Follicle‑stimulating hormone – A pituitary gonadotropin that promotes follicular growth. Elevated basal FSH (measured on cycle day 2–3) can indicate diminished ovarian reserve, whereas low FSH may be seen in hypothalamic‑pituitary dysfunction. In ART cycles, exogenous FSH is administered to stimulate multiple follicle development. Clinicians must balance the dose to avoid ovarian hyperstimulation syndrome (OHSS).

Luteinizing hormone – The pituitary hormone that triggers ovulation and luteinization of the follicle. A mid‑cycle surge in LH is a reliable predictor of imminent ovulation. LH measurement is also useful in diagnosing PCOS, where a persistently elevated LH:FSH ratio may be observed. However, the ratio alone is not diagnostic, and clinicians must consider the full clinical picture.

Estradiol – The primary estrogen produced by the developing follicles. Estradiol levels rise during the follicular phase, peak just before ovulation, and decline thereafter. Monitoring estradiol during COS helps gauge follicular response; excessively high estradiol may increase the risk of OHSS and necessitate cycle cancellation or embryo freezing. Low estradiol in the luteal phase may suggest inadequate luteal function.

Progesterone – The steroid hormone produced by the corpus luteum that supports the secretory transformation of the endometrium. Serum progesterone measured in the mid‑luteal phase (approximately day 21 in a 28‑day cycle) is used to confirm ovulation. Values above 10 ng/mL generally indicate a functional luteal phase, whereas lower values may indicate luteal‑phase deficiency. In ART, supplemental progesterone is routinely given to support implantation.

Prolactin – A pituitary hormone involved in lactation; hyperprolactinemia can suppress GnRH secretion, leading to anovulation. Elevated prolactin levels (usually >25 ng/mL) warrant investigation for pituitary adenomas or medication‑induced causes. Treatment with dopamine agonists (e.G., Cabergoline) often restores ovulatory cycles, but clinicians must monitor for side effects such as hypotension.

Thyroid‑stimulating hormone – The pituitary hormone that regulates thyroid function. Both hypothyroidism (high TSH) and hyperthyroidism (low TSH) can impair fertility by altering menstrual regularity and ovulatory function. Routine pre‑conception screening includes TSH measurement; values outside the reference range (typically 0.4–4.0 MIU/L) may require levothyroxine or antithyroid therapy before attempting conception.

Polycystic ovary syndrome – A heterogeneous endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology on ultrasound. The Rotterdam criteria require two of three features: (1) Oligo‑ or anovulation, (2) clinical or biochemical hyperandrogenism, and (3) ≥12 follicles measuring 2–9 mm in each ovary. PCOS is the most common cause of anovulatory infertility. Management may include lifestyle modification, insulin‑sensitizing agents (e.G., Metformin), and ovulation induction (e.G., Clomiphene citrate).

Endometriosis – The presence of endometrial‑like tissue outside the uterine cavity, which can cause pelvic pain, adhesions, and infertility. Staging (I–IV) is based on the extent of disease observed during laparoscopy. Endometriosis may impair fertility through distorted pelvic anatomy, inflammatory cytokine release, or altered peritoneal environment. Surgical excision can improve natural conception rates, while ART may be indicated for advanced disease.

Uterine factor infertility – Infertility attributable to abnormalities of the uterine cavity, such as congenital malformations, intrauterine adhesions (Asherman’s syndrome), fibroids, or adenomyosis. Hysteroscopic evaluation is the gold standard for diagnosing intrauterine pathology. Treatment options include hysteroscopic resection of fibroids or adhesiolysis; however, recurrence and scarring remain challenges.

Tubal factor infertility – Infertility resulting from obstruction or dysfunction of the fallopian tubes. Common causes include pelvic inflammatory disease (PID), tubal scarring, or congenital anomalies. The gold‑standard diagnostic test is hysterosalpingography (HSG), which visualizes tubal patency using contrast media. Laparoscopy with chromotubation provides direct assessment and may allow for tubal surgery, though the success rates of tubal repair vary widely.

Hysterosalpingography – A radiographic procedure in which iodinated contrast is injected into the uterine cavity to assess the shape of the uterus and the patency of the fallopian tubes. A “spill” of contrast into the peritoneal cavity indicates tubal patency. Pain, allergic reactions to contrast, and radiation exposure are potential drawbacks; thus, a water‑based contrast medium may be used as an alternative.

Hysteroscopy – An endoscopic examination of the uterine cavity performed under direct visualization. It is employed to diagnose and treat intrauterine lesions such as polyps, fibroids, or adhesions. The procedure can be office‑based with minimal anesthesia, offering a rapid diagnostic tool. However, skill level and equipment availability may limit widespread use.

Laparoscopy – A minimally invasive surgical technique that provides visual access to the pelvic organs. It is used both diagnostically (e.G., Assessing endometriosis, tubal patency) and therapeutically (e.G., Cystectomy, adhesiolysis). Advantages include reduced postoperative pain and quicker recovery compared with laparotomy. Limitations involve the need for general anesthesia and potential intra‑abdominal complications.

Transvaginal ultrasound – An imaging modality that uses a high‑frequency probe inserted into the vagina to obtain detailed images of the uterus, ovaries, and adnexa. It is the first‑line tool for evaluating ovarian morphology (e.G., Antral follicle count), endometrial thickness, and the presence of uterine fibroids. Operator skill influences image quality, and interpretation may be subjective.

Three‑dimensional ultrasound – An advanced ultrasound technique that reconstructs volumetric images of the uterus, allowing for precise measurement of uterine anomalies and detailed assessment of the endometrial cavity. It can improve the detection of subtle uterine defects that may be missed on conventional two‑dimensional scans.

Serum anti‑phospholipid antibodies – Autoantibodies associated with antiphospholipid syndrome (APS), a hypercoagulable state that can cause recurrent pregnancy loss and thrombotic events. Testing includes lupus anticoagulant, anticardiolipin, and anti‑β2‑glycoprotein I antibodies. Positive results in the context of recurrent miscarriage may prompt anticoagulation therapy (e.G., Low‑dose aspirin, heparin) to improve pregnancy outcomes.

Genetic testing – The analysis of chromosomal or DNA abnormalities that may affect fertility. Pre‑implantation genetic testing (PGT) can screen embryos for aneuploidy, structural rearrangements, or single‑gene disorders. Karyotyping of both partners is recommended when there is a history of recurrent miscarriage, premature ovarian failure, or known genetic disease. Ethical considerations, cost, and the potential for embryo discard are ongoing challenges.

Semen analysis – The cornerstone male fertility test that evaluates semen volume, sperm concentration, motility, morphology, and vitality. World Health Organization (WHO) reference values define normal parameters (e.G., Concentration ≥15 million/mL, progressive motility ≥40%). Abnormal results may indicate varicocele, obstruction, or endocrine dysfunction. Repeat analysis is essential because parameters can fluctuate due to illness, stress, or abstinence period.

Motility – The percentage of sperm that move actively forward. Progressive motility is particularly important for natural conception and ART. Low motility (asthenozoospermia) may be treated with lifestyle changes, antioxidant supplementation, or assisted techniques such as intracytoplasmic sperm injection (ICSI).

Morphology – The shape and structural integrity of sperm heads, midpieces, and tails. Strict criteria (Kruger's) classify normal morphology as ≥4% of sperm with ideal form. Poor morphology (teratozoospermia) can impair fertilization capacity and may necessitate ICSI. Inter‑laboratory variability in morphology assessment is a common challenge.

Vitality – The proportion of live sperm, assessed by staining techniques (e.G., Eosin‑nigrosin). A vitality <58% may indicate necrospermia, prompting further evaluation for infection or oxidative stress.

DNA fragmentation – The presence of breaks in sperm DNA, measured by assays such as TUNEL or SCSA. High DNA fragmentation index (DFI) (>30%) is associated with reduced fertilization rates, poor embryo quality, and increased miscarriage risk. Interventions include antioxidant therapy, lifestyle modification, and selection of sperm via testicular extraction (TESE) for ICSI.

Varicocele – An abnormal dilation of the pampiniform plexus veins within the scrotum, often contributing to male infertility through increased scrotal temperature and oxidative stress. Physical examination and Doppler ultrasound confirm diagnosis. Surgical repair (varicocelectomy) can improve semen parameters in selected patients, though the degree of improvement varies.

Hypogonadotropic hypogonadism – A condition characterized by insufficient gonadotropin secretion from the pituitary, leading to low testosterone and impaired spermatogenesis. Causes include congenital (Kallmann syndrome), functional (stress, weight loss), or iatrogenic (opioid use). Treatment may involve gonadotropin therapy (hCG and FSH) to stimulate testicular function.

Hyperprolactinemia – Elevated serum prolactin that suppresses gonadotropin‑releasing hormone (GnRH) and disrupts the hypothalamic‑pituitary‑gonadal axis. Besides causing anovulation in women, it can impair testosterone production in men. Dopamine agonists are first‑line therapy, but careful monitoring is required to avoid medication‑induced side effects.

Testicular biopsy – A surgical procedure to obtain tissue from the testis for histologic evaluation or sperm retrieval. It is used in cases of non‑obstructive azoospermia where sperm may be present within the seminiferous tubules. Micro‑TESE (microsurgical testicular sperm extraction) improves sperm yield while minimizing tissue damage. The invasive nature and potential for testicular atrophy are important considerations.

Assisted reproductive technology – A suite of medical interventions that facilitate conception when natural pathways are insufficient. Key modalities include in‑vitro fertilization (IVF), ICSI, and embryo cryopreservation. Success rates depend on age, ovarian reserve, and underlying pathology. Ethical, financial, and emotional aspects must be addressed with patients.

In‑vitro fertilization – The process of retrieving oocytes, fertilizing them with sperm in a laboratory, and transferring resulting embryos into the uterus. Controlled ovarian stimulation protocols aim to obtain multiple mature oocytes, while luteal‑phase support enhances implantation. IVF success is highest in women under 35 and declines with advancing age, largely due to oocyte quality.

Intracytoplasmic sperm injection – A specialized IVF technique in which a single sperm is directly injected into the cytoplasm of a mature oocyte. ICSI is indicated for severe male factor infertility (e.G., Low motility, poor morphology, high DNA fragmentation) and for cases of previous fertilization failure. While ICSI bypasses many sperm defects, it does not correct underlying genetic abnormalities, underscoring the importance of pre‑implantation genetic testing when indicated.

Embryo grading – The morphological assessment of embryos based on cell number, symmetry, fragmentation, and blastocyst development. Graded embryos guide selection for transfer or cryopreservation. However, morphological criteria are imperfect predictors of implantation potential; time‑lapse imaging and metabolic profiling are emerging adjuncts.

Blastocyst transfer – The transfer of embryos at the blastocyst stage (day 5–6) rather than earlier cleavage stages. Blastocyst culture allows for natural selection of embryos with higher developmental competence, improving implantation rates per transfer. The trade‑off is that fewer embryos may reach the blastocyst stage, especially in patients with limited oocyte numbers.

Frozen embryo transfer – The placement of cryopreserved embryos into a prepared uterine environment. Cryopreservation techniques (slow‑freeze, vitrification) have advanced, resulting in survival rates >90%. FET cycles can be programmed (hormone‑replacement) or natural, each with distinct protocols. Recent data suggest comparable or improved outcomes with FET compared with fresh transfer, particularly in high‑responders.

Endometrial receptivity – The state of the endometrium when it is optimally prepared for embryo implantation, typically occurring during the “window of implantation” (days 19–23 of a 28‑day cycle). Markers such as integrin expression, pinopodes, and the ERA (Endometrial Receptivity Analysis) test are used to assess receptivity. In cases of repeated implantation failure, personalized embryo transfer timing based on ERA results may improve success.

Uterine artery Doppler – An ultrasound technique that measures blood flow resistance in the uterine arteries. Low resistance (high pulsatility index) during the luteal phase may correlate with better implantation outcomes. While promising, the predictive value of uterine artery Doppler remains debated, and standardization of measurement protocols is needed.

Menopause – The permanent cessation of ovarian function, defined clinically after 12 consecutive months of amenorrhea. The average age of natural menopause is 51 years, but earlier onset may be due to genetic factors, chemotherapy, or surgical removal of the ovaries (oophorectomy). Menopause marks a transition to reduced estrogen production, influencing bone health, cardiovascular risk, and quality of life.

Perimenopause – The transitional phase leading up to menopause, characterized by irregular menstrual cycles, vasomotor symptoms, and fluctuating hormone levels. Hormone fluctuations can temporarily affect fertility, and women may still conceive during this stage. Accurate dating of the menopausal transition is essential for counseling regarding family planning and contraceptive needs.

Premature ovarian insufficiency – The loss of ovarian function before age 40, presenting with amenorrhea, elevated FSH, and low estradiol. Causes include autoimmune oophoritis, genetic abnormalities (e.G., Turner syndrome), and iatrogenic damage from chemotherapy or radiation. Women with this condition may consider oocyte donation, adoption, or hormone replacement therapy (HRT) for symptom management.

Hormone replacement therapy – The administration of estrogen, with or without progesterone, to alleviate menopausal symptoms and prevent long‑term sequelae such as osteoporosis. In the context of fertility, HRT is not used to induce ovulation but may be employed after oocyte donation to prepare the endometrium for embryo implantation. Risks include thromboembolism and breast cancer, requiring individualized risk‑benefit analysis.

Bone mineral density – A measurement of skeletal strength, often assessed by dual‑energy X‑ray absorptiometry (DEXA). Estrogen deficiency after menopause accelerates bone loss, increasing fracture risk. Fertility specialists should assess bone health in women with premature ovarian insufficiency to initiate appropriate calcium and vitamin D supplementation, along with HRT when indicated.

Cardiovascular risk – The increased likelihood of atherosclerotic disease associated with estrogen decline post‑menopause. While HRT may modestly improve lipid profiles, timing of initiation (the “timing hypothesis”) is critical; early initiation (within 10 years of menopause) may confer cardiovascular benefit, whereas later use may not. Fertility clinicians must coordinate care with primary physicians for comprehensive risk management.

Vasomotor symptoms – Classic menopausal manifestations such as hot flashes and night sweats. Non‑hormonal options (e.G., SSRIs, clonidine) and lifestyle modifications (e.G., Cooling techniques) are alternatives for women contraindicated for HRT. Understanding the impact of these symptoms on quality of life assists in holistic patient counseling.

Sexual dysfunction – Reduced libido, arousal, or pain during intercourse, which can be exacerbated by hormonal changes, psychological stress, or medication side effects. Addressing sexual health is integral to fertility counseling, as it influences partnership dynamics and adherence to treatment.

Fertility preservation – Strategies to safeguard reproductive potential before gonadotoxic therapies (e.G., Chemotherapy, radiotherapy). Options include oocyte or embryo cryopreservation, ovarian tissue freezing, and ovarian suppression with GnRH analogues. Timing, patient age, and disease prognosis determine the appropriate method. Ethical considerations arise when preserving fertility in prepubertal patients.

Ovarian tissue cryopreservation – The surgical removal and freezing of ovarian cortical strips, which contain primordial follicles. This technique is valuable for patients who cannot undergo hormonal stimulation. Reimplantation can restore endocrine function and fertility, though the risk of re‑introducing malignant cells in cancer patients must be assessed.

GnRH agonist protocol – A controlled ovarian stimulation approach that utilizes a GnRH agonist to achieve pituitary desensitization, preventing premature LH surge. It reduces the need for a GnRH antagonist but requires a longer lead‑in period. The protocol is often chosen for patients at high risk of OHSS or those undergoing fertility preservation.

GnRH antagonist protocol – A shorter stimulation regimen in which a GnRH antagonist is administered during the follicular phase to block the LH surge. It offers flexibility and reduces treatment duration, making it popular in many ART cycles. However, careful monitoring is required to avoid luteinizing hormone spikes that could compromise oocyte maturation.

Ovarian hyperstimulation syndrome – A potentially severe iatrogenic complication of COS characterized by ovarian enlargement, fluid shift, and electrolyte imbalance. Risk factors include high estradiol levels, polycystic ovaries, and excessive follicle numbers. Prevention strategies involve using a GnRH antagonist protocol, low‑dose stimulation, or a “freeze‑all” approach to avoid fresh embryo transfer in high‑risk patients.

Freeze‑all strategy – The decision to cryopreserve all embryos from a stimulated cycle and defer transfer to a later, unstimulated cycle. This approach reduces the incidence of OHSS and may improve implantation rates by providing a more physiologic endometrial environment. The downside is a delay in achieving pregnancy and increased cost associated with embryo storage.

Live‑birth rate – The proportion of initiated ART cycles that result in a live birth, considered the most meaningful outcome measure. It differs from clinical pregnancy rate, which includes biochemical pregnancies that may not progress. Live‑birth rate data guide counseling about realistic expectations based on age and treatment type.

Implantation rate – The percentage of transferred embryos that successfully implant, usually calculated per embryo transferred. It reflects both embryo quality and endometrial receptivity. Low implantation rates may prompt investigation of uterine factors, timing of transfer, or the use of adjunctive therapies such as platelet‑rich plasma.

Platelet‑rich plasma – An autologous concentrate of platelets, rich in growth factors, applied intra‑uterinely to enhance endometrial thickness and receptivity. Early studies suggest potential benefits in patients with thin endometrium, but standardized protocols and large‑scale trials are lacking, making its routine use controversial.

Recurrent pregnancy loss – The occurrence of three or more consecutive spontaneous abortions. Evaluation includes assessment for uterine anomalies, antiphospholipid antibodies, thrombophilias, and parental chromosomal abnormalities. Treatment may involve surgical correction of uterine defects, anticoagulation for APS, or pre‑implantation genetic testing to reduce the transmission of aneuploid embryos.

Chromosomal aneuploidy – An abnormal number of chromosomes in the embryo, the most common cause of miscarriage and implantation failure. The incidence of aneuploidy rises sharply after age 35, reaching >50% in oocytes from women in their early 40s. Pre‑implantation genetic testing for aneuploidy (PGT‑A) can identify euploid embryos, improving the chance of a successful pregnancy.

Oocyte donation – The provision of eggs from a screened donor for use in IVF cycles. Indications include premature ovarian insufficiency, advanced maternal age, and severe ovarian failure. Donor screening involves infectious disease testing, genetic counseling, and psychological evaluation. Legal and ethical frameworks differ globally, and recipients must be counseled about potential immunologic and legal considerations.

Embryo adoption – The process by which a couple receives embryos created by another couple, often through a formal agency. It offers an alternative to donor gametes while avoiding the creation of new embryos. Legal contracts, screening for genetic disease, and counseling regarding parental rights are essential components of the process.

Artificial insemination – The placement of sperm directly into the uterine cavity (intrauterine insemination, IUI) or cervix (intracervical insemination, ICI) to facilitate fertilization. Indications include mild male factor infertility, unexplained infertility, and cervical factor issues. Success rates are modest (5–15% per cycle) and decline with age. Proper timing relative to ovulation is critical for optimal outcomes.

Ovulation induction – Pharmacologic stimulation of ovulation using agents such as clomiphene citrate, letrozole, or gonadotropins. Clomiphene, a selective estrogen receptor modulator, is first‑line for many anovulatory patients, while letrozole (an aromatase inhibitor) is increasingly favored due to lower anti‑estrogenic effects on the endometrium. Gonadotropins are reserved for clomiphene‑resistant cases but carry a higher OHSS risk.

Clomiphene citrate – An oral medication that blocks estrogen receptors in the hypothalamus, leading to increased GnRH pulsatility and subsequent FSH rise. Typical dosing starts at 50 mg daily for five days, with monitoring of follicular development via ultrasound. Approximately 70% of women ovulate with clomiphene, yet the pregnancy rate per cycle is lower, reflecting the need for adjunctive interventions.

Letrozole – An aromatase inhibitor that reduces estrogen synthesis, prompting an increase in endogenous gonadotropins. It is particularly effective in women with PCOS and has a favorable side‑effect profile compared with clomiphene. Letrozole also improves endometrial thickness, an advantage for implantation.

Gonadotropin‑releasing hormone analogues – Medications used to control the timing of ovulation and prevent premature LH surges during ART. GnRH agonists cause an initial flare followed by down‑regulation, whereas antagonists provide immediate suppression. Choice of analogue depends on patient characteristics, treatment goals, and risk of OHSS.

Polyspermy – The fertilization of an oocyte by more than one sperm, resulting in an abnormal chromosomal complement and early embryonic arrest. It is rarely observed in natural conception but can occur in IVF when sperm concentration is excessively high. Laboratory protocols limit sperm exposure to minimize polyspermy risk.

Embryo culture media – The nutrient solution that supports embryo development from fertilization to blastocyst stage. Media composition (e.G., Amino acids, growth factors) influences embryo quality, and variations between manufacturers can affect outcomes. Standardization of culture conditions is essential for reproducibility across laboratories.

Embryo transfer catheter – The device used to deposit embryos into the uterine cavity. Soft, flexible catheters reduce trauma and improve placement accuracy. Ultrasound guidance during transfer enhances visualization, but operator skill remains a determinant of success.

Uterine contractility – The spontaneous muscular activity of the uterus, which can influence embryo positioning after transfer. Excessive contractions may expel embryos toward the cervix, decreasing implantation likelihood. Strategies to reduce uterine activity include gentle catheter placement, avoidance of uterine irritants, and, in some protocols, administration of a uterine relaxant (e.G., Atosiban).

Atosiban – An oxytocin‑receptor antagonist used to suppress uterine contractions during embryo transfer. While some studies report improved implantation rates, the evidence remains inconsistent, and routine use is not universally endorsed.

Endometrial thickness – The measurement of the endometrial lining by transvaginal ultrasound, typically expressed in millimeters. A thickness of 7–14 mm is considered optimal for implantation; values below 6 mm are associated with reduced pregnancy rates. Interventions such as estrogen supplementation or PRP may be employed to improve thin endometrium, though robust data are limited.

Uterine blood flow – The perfusion of the uterine tissue, assessed via Doppler ultrasound. Adequate blood flow is essential for delivering nutrients and hormones to the implantation site. Poor flow may be related to uterine artery stenosis or systemic vascular disease, prompting evaluation of cardiovascular health.

Immunologic infertility – A subset of infertility where immune factors (e.G., Anti‑sperm antibodies, natural killer cell activity) interfere with fertilization or implantation. Diagnostic testing includes mixed lymphocyte reaction, NK cell assay, and detection of antisperm antibodies. Therapeutic options such as corticosteroids, intralipids, or IVIG are controversial, with mixed evidence regarding efficacy.

Natural cycle IVF – An IVF approach that utilizes the single naturally selected oocyte without ovarian stimulation. It is advantageous for patients who wish to avoid hormonal exposure or have contraindications to stimulation. Success rates are lower than stimulated cycles, but the method reduces cost, eliminates OHSS risk, and may be combined with cryopreservation of the resulting embryo.

Minimal stimulation IVF – Also known as “micro‑IVF,” this protocol employs low‑dose gonadotropins or oral agents (e.G., Clomiphene) to retrieve a modest number of oocytes. It balances the desire for fewer medications with the need for multiple embryos, offering a compromise between natural and conventional IVF. Patient selection is crucial; those with low ovarian reserve may still benefit.

Time‑lapse imaging – A technology that captures continuous images of embryo development, allowing for kinetic analysis of cell division timing. Certain morphokinetic parameters correlate with higher implantation potential, providing an objective adjunct to traditional morphology grading. However, the equipment cost and need for specialized software limit widespread adoption.

Pre‑implantation genetic testing for monogenic disease – A specialized form of PGT that screens embryos for known single‑gene mutations (e.G., Cystic fibrosis, Huntington’s disease). Couples with a known genetic risk undergo IVF with embryo biopsy, and unaffected embryos are selected for transfer. Ethical counseling is vital, as the process raises concerns about selection and the potential for discarding embryos.

Pre‑implantation genetic testing for structural rearrangements – PGT‑SR identifies embryos carrying balanced translocations or inversions inherited from a parent. This testing reduces the risk of miscarriage due to unbalanced chromosomal content and improves the chance of a healthy live birth. Accurate parental karyotyping is required to guide the analysis.

Embryo mosaicism – The presence of both euploid and aneuploid cell lines within a single embryo. Mosaic embryos can result in viable pregnancies, though the risk of abnormal outcomes is higher. Recent evidence suggests that some mosaic embryos may be transferred safely, but thorough counseling and careful selection are essential.

PGT‑A versus PGT‑M – PGT‑A (for aneuploidy) screens for chromosome number abnormalities, while PGT‑M (for monogenic disease) targets specific gene mutations. The choice depends on the clinical indication: Advanced maternal age or recurrent miscarriage typically leads to PGT‑A, whereas a known inherited disorder leads to PGT‑M. Both require embryo biopsy at the blastomere or trophectoderm stage.

Embryo biopsy – The removal of one or a few cells from an embryo for genetic analysis. Trophectoderm biopsy (performed at the blastocyst stage) yields more cells and is less likely to impair developmental potential compared with cleavage‑stage biopsy. The procedure demands skilled embryologists and strict aseptic technique to prevent contamination.

Cryopreservation – The process of freezing biological material for later use. In ART, vitrification (ultra‑rapid freezing) has largely replaced slow‑freeze methods due to higher survival rates and reduced ice crystal formation. Successful cryopreservation is critical for embryo banking, fertility preservation, and the “freeze‑all” strategy.

Vitrification – A cryopreservation technique involving exposure of embryos or oocytes to high concentrations of cryoprotectants followed by rapid cooling, resulting in a glass‑like solid state. It minimizes cellular damage and has become the standard for both embryo and oocyte storage. Proper handling of cryoprotectants is essential to avoid toxicity.

Oocyte vitrification – The freezing of mature oocytes for future use. It is particularly valuable for women delaying childbearing or undergoing gonadotoxic therapy. Survival rates after thaw range from 80–90%, and fertilization rates are comparable to fresh oocytes when performed by experienced laboratories. However, the cumulative live‑birth rate per vitrified oocyte remains lower than that of fresh cycles, emphasizing the need for realistic counseling.

Ovarian stimulation protocols – Structured regimens that employ exogenous hormones to induce follicular development. Common protocols include the long GnRH‑agonist protocol, the short antagonist protocol, and the mild stimulation protocol. Selection is based on patient age, ovarian reserve, and risk of OHSS. Monitoring includes serial ultrasound and hormone measurements to adjust medication dosing.

Follicular monitoring – Serial transvaginal ultrasounds to track follicle size, number, and growth rate during COS. This monitoring guides the timing of hCG trigger (or GnRH agonist trigger) to achieve optimal oocyte maturity. Inadequate monitoring can lead to premature ovulation or retrieval of immature oocytes.

hCG trigger – The administration of human chorionic gonadotropin to mimic the natural LH surge, inducing final oocyte maturation. The usual dose is 5,000–10,000 IU, given 36 hours before oocyte retrieval. In high‑risk OHSS patients, a GnRH agonist trigger may be used instead to reduce estrogen exposure.

GnRH agonist trigger – An alternative to hCG that induces an endogenous LH surge through GnRH receptor activation. It dramatically lowers OHSS incidence but may compromise luteal support; therefore, intensive luteal-phase supplementation (e.G., High‑dose progesterone and estradiol) is required to maintain implantation potential.

Luteal‑phase support – Hormonal supplementation after oocyte retrieval to sustain the endometrium until placental takeover. Common regimens include vaginal progesterone, intramuscular progesterone, and oral estradiol. Adequate support is crucial, as insufficient luteal function can lead to early pregnancy loss even when high‑quality embryos are transferred.

Embryo transfer timing – The decision to transfer embryos on day 3 (cleavage stage) versus day 5‑6 (blastocyst stage). Day‑5 transfer aligns with the natural implantation window and may improve implantation rates, but fewer embryos may survive to blastocyst in patients with limited oocyte numbers. Day 3 transfer offers a higher number of embryos for selection but may increase the risk of multiple gestations if more than one embryo is transferred.

Multiple gestation risk – The probability of twins, triplets, or higher-order pregnancies, which increases with the number of embryos transferred.